Disease · MONDO_0021085
Trials65
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
1 to 20 of 65
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00400179 | A Safety and Efficacy Study in Patients With Gastric Cancer | Phase 3 | 1,053 | 2012-04-23 | Gastric Cancer | CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT03382600 | Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) | Phase 2 | 100 | 2023-12-01 | Gastric Cancer | CISPLATIN, OTERACIL, OXALIPLATIN, PEMBROLIZUMAB, TEGAFUR | Its record names the disease | ClinicalTrials.gov |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | Phase 2/3 | 82 | 2025-04-22 | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer | MARGETUXIMAB, RETIFANLIMAB, TEBOTELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05014828 | To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors | Phase 2 | 58 | 2025-08-24 | Advanced Solid Tumor | LENVATINIB, TISLELIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | Phase 2 | 35 | 2017-12-13 | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma | OXALIPLATIN, PRALATREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT00514020 | Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer | Phase 2 | 33 | 2012-10-18 | Gastric Cancer | FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00496860 | Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies | Phase 1 | 26 | 2013-07-15 | Progressive Metastatic Malignancies | PEMVIDUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | Phase 2 | 20 | 2022-09-07 | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage IA Esophageal Cancer, Stage IA Gastric Cancer, Stage IB Esophageal Cancer, Stage IB Gastric Cancer, Stage IIA Esophageal Cancer, Stage IIA Gastric Cancer, Stage IIB Esophageal Cancer, Stage IIB Gastric Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT04798781 | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | Phase 2 | 16 | 2024-10-10 | Gastric Cancer, Hepatocellular Carcinoma | PEMBROLIZUMAB, TELATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Phase 2 | 14 | 2022-06-30 | Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7 | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00335959 | S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery | Phase 2 | 7 | 2012-08-17 | Gastric Cancer | CAPECITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03006705 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | Phase 3 | 800 | Gastric Cancer | CAPECITABINE, NIVOLUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02746796 | Study of ONO-4538 in Gastric Cancer | Phase 2/3 | 680 | Gastric Cancer | CAPECITABINE, NIVOLUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05144854 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | Phase 3 | 626 | Gastric Cancer | CAPECITABINE, IPILIMUMAB, NIVOLUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00824785 | REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer | Phase 3 | 574 | Oesophago-gastric Cancer | CAPECITABINE, EPIRUBICIN, OXALIPLATIN, PANITUMUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | Phase 3 | 547 | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | BEMARITUZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. | Phase 3 | 515 | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | BEMARITUZUMAB, CAPECITABINE, FLUOROURACIL, LEUCOVORIN, NIVOLUMAB, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02267343 | Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer | Phase 3 | 493 | Gastric Cancer | NIVOLUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | 454 | Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer | BEVACIZUMAB, CAPECITABINE, CARBOPLATIN, CISPLATIN, DATOPOTAMAB DERUXTECAN, FLUOROURACIL, LEUCOVORIN, PREDNISONE, RILVEGOSTOMIG, VOLRUSTOMIG | Its record names the disease | ClinicalTrials.gov | |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | 452 | Gastric Cancer | CAPECITABINE, CISPLATIN, DURVALUMAB, FLUOROURACIL, OXALIPLATIN, PEMBROLIZUMAB, RILVEGOSTOMIG, TRASTUZUMAB DERUXTECAN, VOLRUSTOMIG | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021085/trials